Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma
Immune checkpoint inhibitors (ICPi) targeting the PD-1/PD-L1 pathway have shown marked success in patients with advanced melanoma. However, 60–70% of patients fail to respond, warranting a therapeutic intervention that could increase response rates. We and others have shown that S-adenosylmethionine...
Gardado en:
| Principais autores: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Media S.A.
2020-09-01
|
| Series: | Frontiers in Oncology |
| Assuntos: | |
| Acceso en liña: | https://www.frontiersin.org/article/10.3389/fonc.2020.01361/full |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|